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Summary
Objectives: Mortality among HIV patients with tuberculosis (TB) remains high in Eastern 
Europe (EE), but details of TB and HIV management remain scarce.
Methods: In this prospective study, we describe the TB treatment regimens of patients with 
multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART).
Results: A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug 
resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of 
patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, 
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an estimated 57.3% (95%CI 41.5–74.1) of MDR-TB patients had started adequate treatment. 
While 67% received ART, HIV-RNA suppression was demonstrated in only 23%.
Conclusions: Our results show that internationally recommended MDR-TB treatment regimens 
were infrequently used and that ART use and viral suppression was well below the target of 90%, 
reflecting the challenging patient population and the environment in which health care is provided. 
Urgent improvement of management of patients with TB/HIV in EE, in particular for those with 
MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and 
use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of 
TB/HIV care.
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Introduction
Although rates of tuberculosis (TB) have begun to decline in recent years, simultaneous 
rapid increases in the relative contribution of multi-drug resistant TB (MDR-TB) and 
extensively drug resistant TB (XDR-TB) are worrying.1–4 Eastern Europe (EE), together 
with central Asia, has the worlds’ highest proportions of MDR- and XDR-TB with 9–35% 
of new TB cases and 49–77% of re-treatment cases being diagnosed with MDR-TB in 
Belarus, Russia and Ukraine compared with 1–3% of new cases and 4–14% of re-treatment 
cases in Italy, Switzerland and the United Kingdom.1,5–8
The MDR-TB epidemic in EE is further complicated by high rates of HIV co-infection. 
Whereas most other regions have reported declining rates of new HIV infections over recent 
years, EE has experienced an increase of 30% in annual number of new HIV infections since 
the turn of the millennium.9,10 The TB/HIV epidemic in EE is primarily driven by injection 
drug users (IDU) who often access health care late, are co-infected with hepatitis C (HCV), 
and frequently have poor treatment compliance and retention in care.11–14 We recently 
reported a one-year mortality rate of 27% for TB/HIV co-infected patients in EE, and 
patients diagnosed with MDR-TB had roughly three-times higher mortality compared to 
those with drug-susceptible TB. Further, patients from EE who initiated TB treatment with 
three or more active drugs had significantly lower risk of death compared to patients who 
received less than three active TB drugs (13% vs 34%).15
Treatment for MDR-TB is complex in terms of pill burden, drug-interactions and toxicity, 
and costly.1,16–18 MDR-TB therapy is prolonged (typically at least 20 months) although the 
2016 WHO guidelines include an option for shorter MDR-TB regimens in specific cases.
16,19
 Preliminary results with a novel six months regimen (consisting of pretomanid, 
bedaquiline and linezolid) may be highly effective to treat MDR-TB.20 For now, standard of 
care consists of at least five drugs including a fluoroquinolone, a second-line injectable, at 
least two other active drugs plus pyrazinamide during the intensive phase of treatment.19 
Reported MDR-TB treatment success rates, however, have been generally low, in particular 
for HIV-positive individuals, and rarely exceed 50%.18,21
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Epidemiological data and detailed descriptions of the clinical management of HIV-positive 
patients with MDR-TB in EE remain relatively scarce.22 We prospectively studied patients 
with TB/HIV co-infection in EE and in this paper report on the management of those with 
MDR-TB.
Methods
Study design and participants
The TB:HIV Study is a prospective cohort study including 62 TB and HIV clinics in 19 
countries in EE, Western Europe, Southern Europe, and Latin America. Adult (>16 years) 
HIV-positive patients with a TB diagnosis were consecutively enrolled between 01/01/2011 
and 31/12/2013. Demographic, clinical, and laboratory data were collected on standardized 
case report forms at baseline and month 6, 12, and 2412; further details are available at http://
www.cphiv.dk/TBHIV. All participating clinics obtained ethical approval in accordance with 
local rules and legislations, and the study was performed in accordance with the strobe 
guidelines for observational studies.23
Study definitions
Patients from EE were included in the present analyses if they had definite or probable TB. 
A diagnosis of definite TB was based on positive culture or molecular diagnostics for 
Mycobacterium tuberculosis (Mtb), and probable TB on the presence of acid fast bacilli 
and/or granulomatous inflammation on sputum smear or tissue biopsy specimens.12 
Baseline was defined as the date TB treatment was initiated, and a baseline culture was 
defined as a culture obtained within one month of baseline. All TB drugs initiated within 10 
days of baseline were considered to constitute initial TB treatment. Standard definitions of 
MDR-TB, pre-XDR-TB, and XDR-TB were used (see Box 1), and pan-susceptible TB was 
defined as TB without documented drug resistance. TB treatment regimens were categorized 
in line with general recommendations16,24: 1: Treatment regimens containing RHZ (with or 
without ES) targeting drug-susceptible TB,24 2: Treatment regimens containing RHZ plus a 
fluoroquinolone AND a second line injectable, providing empiric cover for both susceptible 
TB and MDR-TB, 3: Five or more MDR-TB drugs (including a fluoroquinolone AND a 
second line injectable) providing appropriate empiric cover for MDR-TB, 4: Regimens 
containing a fluoroquinolone OR a second line injectable (but not both), providing 
inadequate cover for MDR-TB, and 5: Any other drug combination (Fig. 1). For patients 
with MDR-TB, the number of active drugs in the TB regimen was calculated at various time 
points based on the susceptibility pattern of isolates obtained up to the given time point. If a 
Drug Susceptibility Test (DST) result was not available for a specific drug included in the 
regimen, the given Mtb isolate was either considered potentially susceptible to this drug 
(potentially active drugs) or resistant to this drug (known active drugs), thus representing a 
“best case” and “worst case” treatment scenario.
Antiretroviral treatment (ART) was defined as a combination of ≥ 3 antiretroviral drugs from 
any ART class. Participants were considered lost to follow-up (LTFU) when no attendance 
was recorded at the relevant time points in those who were not known to have died.
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Statistical analysis
Descriptive statistics were used for baseline characteristics of patients. Patients were 
stratified into three groups: MDR-TB at baseline, pan-susceptible TB at baseline, and other 
(no baseline DST results available or the presence of non-MDR-TB resistance patterns). 
MDR-TB patients who had extended DST available were further classified as having pre-
XDR or XDR-TB. Baseline characteristics among patients who had MDR-TB, those who 
were fully susceptible and those who did not have any baseline DST available were 
compared using the chi-squared test or Fisher’s exact test as appropriate for categorical 
variables, whereas the Kruskal–Wallis test was used to compare continuous variables.
TB and HIV treatment regimens were analyzed at months 0, 3, 7, 13, and 21. Kaplan–Meier 
estimates were used to estimate time to receiving adequate treatment for MDR-TB (category 
3: five or more MDR-TB drugs including a fluoroquinolone AND a second line injectable), 
and time to starting ART censoring at last visit date (maximum 21 months) or death, 
whichever occurred first. Further, Kaplan–Meier estimates were also used to estimate the 
time to starting ART. All statistical analyses were performed using SAS (Statistical Analysis 
Software, Cary, NC, USA, version 9.3).
Results
Patient characteristics
Of 1406 patients enrolled into the TB:HIV study, 834 received care in EE, of these 485 had 
definite or probable TB and were included in this analysis (Supplementary Fig. S1). A 
positive culture for Mtb was reported in 383 (79%) patients, 302 (79%) of these were tested 
for resistance to any drug, 270 (70%) for both R and H, and 68 (18%) for fluoroquinolone or 
second line injectables. Of the 485 patients, 105 (22%) had MDR-TB, 130 (27%) had pan-
susceptible TB at baseline and 183 (38%) had no DST results; the remaining 67 (14%) had 
non-MDR-TB resistance patterns and were excluded from subsequent analyses. Baseline 
characteristics are shown in Table 1. The majority of patients were male and white, with a 
median age of 35 years. Recent incarceration was common, and previous TB, IDU, and 
HCV co-infection were significantly more common among MDR-TB patients. The median 
baseline CD4 cell count was 91 (interquartile range [IQR] 31–230) cells/mm3, and only 82 
(17%) patients were on ART.
DST patterns for MDR-TB patients
Among the 105 patients with MDR-TB at baseline, DST results (obtained at any time during 
TB treatment) for other drugs ranged from 51–95% for group 1 drugs, 75–78% for group 2/3 
drugs, and 49–69% for group 4 drugs (Table 2). The timing of DST testing for individual TB 
drugs is shown in Table 3a. Overall, 13 (12%) of MDR-TB patients had XDR-TB, 20 (19%) 
had pre-XDR, 35 (33%) had MDR, and 37 patients had insufficient data to determine pre-
XDR/XDR-TB status.
Treatment regimen and outcomes
In Fig. 1, TB treatment regimens and outcomes are depicted from baseline through 21 
months of follow-up. WHO recommended regimens were initiated in the majority of 
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individuals with drug-susceptible TB but maintained well beyond the recommended 6 
months. Despite the high population prevalence of MDR-TB, very few subjects received 
empiric therapy that provided cover against drug-susceptible and (multi)drug resistant TB 
(category 2). High rates of death were observed among MDR-TB patients and those without 
DST. Loss to follow-up (from both TB and HIV care) was high, ranging from 8% of MDR-
TB patients to 19–20% among patients with pan-susceptible TB or no DST.
TB treatment for MDR-TB patients
Only 8 (8%) of MDR-TB patients initiated an adequate empiric MDR-TB regimen (category 
3), which increased to 35 (44% of patients still under follow-up) after three months. A total 
of 49 MDR-TB patients ever received category 3 treatment after a median of 1.2 months 
(IQR 0.4–2.3), and by 12 months, an estimated 57.3% (95%CI = 41.5–74.1%) had started 
adequate MDR-TB treatment. Similar results were obtained when excluding patients with 
known pre-XDR-TB or XDR-TB (data not shown).
Fluoroquinolones and second-line injectables were uncommon components of initial 
treatment and, if used, commonly used without adequate companion drugs (Table 3b/c). By 
three months, a quarter of MDR-TB patients still had not initiated a fluoroquinolone or a 
second-line injectable. Group 4 drugs were variably used, a single patient had received 
linezolid (introduced late during the course of treatment), and no patients had received 
bedaquiline or delamanide. Culture conversion was documented in 45/105 (43%) of MDR-
TB patients and 77/130 (59%) of patients with pan-susceptible TB after a median of 3.0 
(IQR 1.8–5.1) and 2.3 (IQR 1.7–4.9, p = 0.30) months, respectively.
Activity of TB treatment for MDR-TB patients
Fig. 2a–c illustrates the total number of drugs and the total number of “potentially” active 
drugs and “known” active drugs, respectively, in the MDR-TB treatment regimens. While 
most patients received 4 or more drugs in their regimen during the first year of treatment, 
more than 70% received 0, 1 or 2 drugs with demonstrated activity. A regimen containing 5 
or more known active drugs was received by less than 15% of patients and a regimen 
containing 5 or more potentially active drugs by less than 40% of patients.
HIV treatment for MDR-TB patients
Despite 77% of MDR-TB patients at the time of their TB diagnosis already having an HIV 
diagnosis and the majority being severely immunosuppressed with a median CD4 cell count 
of 100 cells/mm3, only 13% were on ART at baseline (Table 1). The proportion on ART 
among those who remained in care increased to more than 60% (Fig. 3). The majority of 
those on ART did not have regular HIV-RNA monitoring, and less than 20% of MDR-TB 
patients were documented to have had an undetectable HIV-RNA (<500 copies/mL) at any 
stage during follow up. The Kaplan-Meier estimate of starting ART by eight weeks was only 
23%; similar results were observed for patients with drug-susceptible TB and those with no 
DST results (data not shown).
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Discussion
This study shows suboptimal management of MDR-TB in HIV-positive patients in EE. 
Despite the high prevalence of MDR-TB, full DST testing was often restricted and delayed, 
resulting in prolonged use of inappropriate or failing regimens that contained few active 
drugs and suboptimal intensification strategies, with only half of patients ultimately 
receiving recommended MDR-TB therapy. In addition, we observed a low uptake of ART, 
inadequate viral load monitoring and low rates of HIV-RNA suppression. All of these factors 
are likely to have contributed to the mortality rate of nearly 50% at two years. These data 
point towards opportunities to improve management of HIV-positive individuals with TB in 
parts of EE.
The similar characteristics of patients with and without MDR-TB preclude public health 
strategies based on risk-stratification of patients and argue for routine DST in all TB 
patients. Rapid TB diagnostics and DST such as line-probe assays or cartridge-based 
molecular tests for Mtb and rifampicin resistance16 should be introduced as a priority,25 with 
routine evaluation of genotypic or phenotypic DST for fluoroquinolones and second line 
injectables of all rifampicin-resistant isolates. Thirty-nine percent of those tested for MDR-
TB in our cohort had MDR-TB which is consistent with other recent reports from the EE 
region.8,26 Of the patients with MDR-TB, approximately one-third had MDR, one-third had 
pre-XDR or XDR-TB, and one-third did not have sufficient DST data to assess whether they 
had (pre-)XDR-TB. We also found common co-resistance to other drugs, as described in 
another European multicenter study.27 Despite the setting of high MDR-TB prevalence in 
EE, empiric therapy rarely provided cover for MDR-TB. This is also problematic as 
selection for additional drug-resistance is more likely to occur early on when the bacillary 
burden is high. It is worth noting, however, that four in five patients who later were shown to 
have fully susceptible TB, initially received adequate RHZ-based treat-ment, as recently 
described.28
In patients with MDR-TB, there were significant delays to initiate treatment for MDR-TB, 
and many patients never received adequate MDR-TB treatment as defined by international 
guidelines.19 The number of active drugs remained low at all time points; only one-third of 
patients were treated at some stage with at least five potentially active drugs, and only one-
sixth of patients received regimens with 5 drugs known to have activity against their Mtb 
isolate. This is of concern as recent studies demonstrate improved outcomes with optimal 
MDR-TB regimens (≥5 likely effective drugs).29–31 Optimal MDR-TB treatment requires 
continued, unrestricted access to high quality medications; in a recent survey we 
documented that this was not the case in many clinics in EE.32 In agreement with this, 
linezolid, bedaquiline and delamanid were generally not used although widespread use in the 
current context raises significant opportunities for these drugs to be rapidly lost due to the 
emergence of resistance.
There is now solid evidence that ART should be initiated shortly after TB diagnosis, 
especially in patients with MDR-TB and those with CD4 cell counts below 50 cells/
mm3.33–36 In our study, patients were severely immunosuppressed, and two-thirds of those 
who remained under follow-up at three months had initiated ART. However, less than 20% 
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had documented suppressed viral loads at any time which is well short of the WHO goal of 
virological suppression in 90% of patients receiving ART.37
We documented a mortality rate of nearly 50% within the first two years following initiation 
of TB treatment, which is similar to the mortality observed in a retrospective study from our 
group of HIV-patients with MDR-TB in EE which was conducted in the period 2004–
2006.14 Retrospective African studies reported mortality rates among HIV-positive patients 
with MDR-TB of 15–31%38–40 and a meta-analysis of outcomes found a pooled mortality 
rate of 38%.41 The vast majority of deaths in our retrospective cohort were due to TB,42 
which underscores the particular need for high-quality TB management for people with HIV. 
Other circumstances may have played a role in determining outcome of MDR-TB patients in 
EE. A disintegrated health care system with separated TB and HIV management remains 
common32 and is likely to contribute to poor coordination of care to this often very 
vulnerable patient population. In particular, opioid substitution therapy for IDU is severely 
restricted or even prohibited in some countries despite documented positive effects on 
adherence to treatment and health care in general.43
Our observational study has several limitations including the intrinsic risk of selection bias. 
The participating clinics were primarily located in major cities and may not be 
representative of all clinics across EE. DST was done locally and methods for performing 
DSTs varied between clinics, and when calculating the number of active drugs, we counted 
all drugs as equally effective which is likely to be an over-simplification. A large number of 
patients had missing DST results, CD4 cell counts and HIV-RNA measurements precluding 
a more robust evaluation of immune-virological outcomes. Nonetheless, the circumstances 
described reflect the difficulties for many HIV and TB clinicians working in EE, although 
substantial regional variability in the prevalence of MDR-TB and availability of DST, TB 
and ART drugs, and HIV-RNA measurements exists.12 Due to limited number of patients 
with MDR-TB we did not assess intraregional variability.
Conclusion
In EE, there is an urgent need for access to rapid diagnostics to guide initial TB treatment, to 
extend DST to all patients diagnosed with rifamycin-resistant or MDR-TB and to provide 
better access to second line drugs to allow the administration of optimally active MDR-TB 
regimens. Integration of TB and HIV services can ensure better management and support for 
people with HIV who frequently have IDU and HCV coinfection, including rapid initiation 
of fully suppressive ART.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Box 1
Definitions of tuberculosis resistance
Definition
Multidrug-resistant
 tuberculosis (MDR-TB)
Tuberculosis resistant to
rifampicin and isoniazid
Pre-extensively drug-
 resistant tuberculosis
 (pre-XDR-TB)
MDR-TB plus additional
resistance against a
fluoroquinolone or a
second-line injectable
Extensively drug-
 resistant tuberculosis
 (XDR-TB)
MDR-TB plus additional
resistance against a
fluoroquinolone and a
second-line injectable
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Figure 1. 
TB treatment and outcomes over time among 105 patients with MDR-TB (left), 183 with no 
DST (middle) and 130 patients with susceptible TB (right) from time of start of TB 
treatment.
R = Rifampicin
H = Isoniazid
Z = Pyrazinamide
E = Ethambutol
S = Streptomycin
FQ = Fluoroquinolone
2L-inj = Second-line injectables
LTFU = Loss to follow-up
DST = Drug-susceptibility test
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Figure 2. 
a-c: Number of total TB drugs (a), potentially active* (b), and known active** (c) TB drugs 
at each time point for 105 MDR-TB patients under follow-up.
*Potentially active: Assuming susceptibility where DST for a specific drug was missing.
**Known active: Only including known DST results and not assuming susceptibility for 
missing DST.
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Figure 3. 
Antiretroviral (ART) status over time for MDR-TB patients (N = 105)*
*ART and viral load (VL) was calculated +/− 1 month of the various time-points.
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Table 2
Results from drug susceptibility test performed at any time point in follow-up among all patients with MDR-
TB (N = 105)
Drug N (%)
with data
N (% of those
tested) with
resistance
Group 1
Pyrazinamide  54 (51) 30 (56)
Ethambutol 100 (95) 72 (72)
Streptomycin  75 (71) 72 (96)
Group 2
Fluoroquinolones  79 (75) 22 (28)
Group 3
Second-line injectables  82 (78) 35 (43)
Group 4
Ethionamide/Prothionamide  72 (69) 23 (32)
Cycloserine/Terizidone  51 (49)  8 (16)
Para-Aminosalicylic Acid (PAS)  61 (58) 10 (16)
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